Decline in opioid prescribing after federal rescheduling of hydrocodone products
- 21 December 2017
- journal article
- research article
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 27 (5) , 513-519
Abstract
Purpose: To examine differences in opioid prescribing by patient characteristics and variation in hydrocodone combination product (HCP) prescribing attributed to states, before and after the 2014 Drug Enforcement Administration's reclassification of HCP from schedule III to the more restrictive schedule II.Methods: We used 2013 to 2015 data for 9 202 958 patients aged 18 to 64 from a large nationally representative commercial health insurance program to assess the temporal trends in the monthly rate of opioid prescribing.Results: HCP prescribing decreased by 26% from June 2013 to June 2015; the rate of prescriptions for any opioid decreased by 11%. Prescribing of non‐hydrocodone schedule III opioids increased slightly while prescribing of non‐hydrocodone schedule II opioids and tramadol was stable. Absolute decreases in HCP prescribing rates were larger in patients being treated for cancer (−2.26% vs −0.7% for non‐cancer patients, P < 0.0001) and in those with high comorbidities (−2.13% vs −0.55% for those with no comorbidity, P < 0.0001). Differences in the absolute and relative changes in HCP prescribing rates among states were large; for example, a relative decrease of 46.7% in Texas and a 12.7% increase in South Dakota. The variation in HCP prescribing attributable to the state of residence increased from 6.6% in 2013 to 8.7% in 2015.Conclusions: The 2014 federal policy was associated with a decrease in rates of HCP and total opioid prescribing. The large decrease in the rates of HCP prescribing for patients with actively treated cancer may represent an unintended consequence.Keywords
Funding Information
- National Institutes of Health (K05-CA134923, P30-AG024832, R01-AG033134, R01-DA039192, UL1TR001439)
- Agency for Healthcare Research and Quality (R24-HS022134)
This publication has 41 references indexed in Scilit:
- What we know, and don’t know, about the impact of state policy and systems-level interventions on prescription drug overdoseDrug and Alcohol Dependence, 2014
- Impact of legislation and a prescription monitoring program on the prevalence of potentially inappropriate prescriptions for monitored drugs in Ontario: a time series analysisCMAJ Open, 2014
- The Changing Face of Heroin Use in the United StatesJAMA Psychiatry, 2014
- Trends in Androgen Prescribing in the United States, 2001 to 2011JAMA Internal Medicine, 2013
- Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPCThe Lancet Oncology, 2012
- Bending the prescription opioid dosing and mortality curves: Impact of the Washington State opioid dosing guidelineAmerican Journal of Industrial Medicine, 2011
- Differences and over‐time changes in levels of prescription opioid analgesic dispensing from retail pharmacies in Canada, 2005–2010Pharmacoepidemiology and Drug Safety, 2011
- Age and Gender Trends in Long-Term Opioid Analgesic Use for Noncancer PainAmerican Journal of Public Health, 2010
- Effect of Scheduling Tramadol as a Controlled Substance on Poison Center Exposures to TramadolAnnals of Pharmacotherapy, 2010
- American Pain Society Recommendations for Improving the Quality of Acute and Cancer Pain ManagementArchives of internal medicine (1960), 2005